Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2008-02-06
2009-06-09
Woodward, M P (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S401000
Reexamination Certificate
active
07544372
ABSTRACT:
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration-time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
REFERENCES:
patent: 3882246 (1975-05-01), Share
patent: 4590062 (1986-05-01), Jang
patent: 4728513 (1988-03-01), Ventouras
patent: 4743248 (1988-05-01), Bartoo et al.
patent: 4780319 (1988-10-01), Zentner et al.
patent: 4789549 (1988-12-01), Khan et al.
patent: 4795644 (1989-01-01), Zentner
patent: 4814183 (1989-03-01), Zentner
patent: 4839177 (1989-06-01), Colombo et al.
patent: 4851228 (1989-07-01), Zentner et al.
patent: 4851229 (1989-07-01), Magruder et al.
patent: 4882167 (1989-11-01), Jang
patent: 4996047 (1991-02-01), Kelleher et al.
patent: 5008114 (1991-04-01), Loverecich
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5260069 (1993-11-01), Chen
patent: 5350584 (1994-09-01), McClelland et al.
patent: 5366738 (1994-11-01), Rork et al.
patent: 5407686 (1995-04-01), Patel et al.
patent: 5422122 (1995-06-01), Powell
patent: 5582838 (1996-12-01), Rork et al.
patent: 5874418 (1999-02-01), Stella et al.
patent: 5882682 (1999-03-01), Rork et al.
patent: 5952451 (1999-09-01), Zhao
patent: 6004582 (1999-12-01), Faour et al.
patent: 6020000 (2000-02-01), Wong et al.
patent: 6344215 (2002-02-01), Bettman et al.
patent: 6451345 (2002-09-01), Percel et al.
patent: 6500454 (2002-12-01), Percel et al.
patent: 6627223 (2003-09-01), Percel et al.
patent: 6663888 (2003-12-01), Percel et al.
patent: 7387793 (2008-06-01), Venkatesh et al.
patent: 2003/0099711 (2003-05-01), Meadows et al.
patent: 2003/0215496 (2003-11-01), Patel et al.
patent: 2004/0126427 (2004-07-01), Venkatesh et al.
patent: 2004/0166160 (2004-08-01), Subramanian et al.
patent: 2004/0197407 (2004-10-01), Subramanian et al.
patent: 2005/0013860 (2005-01-01), Venkatesh et al.
patent: 2005/0106247 (2005-05-01), Venkatesh et al.
patent: 2008/0124398 (2008-05-01), Venkatesh et al.
patent: 0518263 (1992-12-01), None
patent: WO 98/06439 (1998-02-01), None
patent: WO 98/18610 (1998-05-01), None
patent: WO 98/53802 (1998-12-01), None
patent: WO 99/12524 (1999-03-01), None
patent: WO 99/18937 (1999-04-01), None
patent: WO 99/30671 (1999-06-01), None
patent: WO 01/15668 (2001-03-01), None
patent: WO 03/020242 (2003-03-01), None
Akimoto, M. et al., “Evaluation of sustained-release granules of chlorphenesin carbamate in dogs and humans,” International Journal of Pharmaceutics, 100, pp. 133-142 (1993).
International Search Report; PCT/US06/037266; Jun. 14, 2005.
Rowe et al., “Ethylcellulose,” Handbook of Pharmaceutical Excipients, 5th ed., London: Pharmaceutical Press (2006), pp. 278-279.
Rekhi and Jambhekar, “Ethylcellulose - A Polymer Review,” Drug Development and Industrial Pharmacy 21:61-77 (1995).
Excerpt from U.S. Pharmacopeia XXIV (1999), pp. xxvi-xxxvi (p. xxvii cited in Section I(A)(1) of C4).
Detailed Factual and Legal Basis for Paragraph IV Certification Regarding United States Patent No. 7,387,793 (included in generic pharmaceutical company's Notice Letter dated Oct. 28, 2008.
Complaint for Patent Infringement inEurand, Inc., Cephalon, Inc., and Anesta AGv.Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Nov. 25, 2008.
Complaint for Patent Infringement inEurand, Inc., Cephalon, Inc., and Anesia AGv.Mylan Pharmaceuticals, Inc. and Mylan, Inc., Civil Action No. 1:08-cv-00210-IMK, filed with the United States District Court for the Northern District of West Virginia on Nov. 26, 2008.
Copending U.S. Appl. No,. 12/026,882 (continuation of U.S. Appl. No. 10/713,929), filed Feb. 6, 2008.
Copending U.S. Appl. No. 12/236,719 (divisional of U.S. Appl. No. 10/713,929), filed Sep. 24, 2008.
Copending U.S. Appl. No. 12/236,723 (continuation of U.S. Appl. No. 10,713,929) filed Sep. 24, 2008.
Complaint for Patent Infringement inEurand, Inc., Cephalon, Inc., and Anesta AGv.Impax Laboratories, Inc., Civil Action No. 1:09-cv-00018-SLR, filed with the United States District Court for the District of Delaware on Jan. 7, 2009.
Answer and Counterclaim of Impax Laboratories, Inc. inEurand, Inc., Cephalon, Inc., and Anesta AGv.Impax Laboratories, Inc., Civil Action No. 1:09-cv-00018-SLR, filed with the United States District Court for the District of Delaware on Jan. 26, 2009.
Answer, Defenses, and Counterclaims of Mylan, Inc. and Mylan Pharmaceuticals, Inc.,Eurand, Inc., Cephalon, Inc., and Anesta AGv.Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Dec. 16, 2008.
Barr Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims,Eurand, Inc., Cephalon, Inc., and Anesta AGv.Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Dec. 16, 2008.
Eurand, Inc. and Anesta AG's Answers to Defendant Barr Laboratories, Inc.'s Counterclaims,Cephalon, Inc., and Anesta AGv.Mylan Pharmaceuticals, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Jan. 8, 2009.
Eurand, Inc., Cephalon, Inc., and Anesta AG's Answers tand Affirmative Defenses to Mylan Inc. and Mylan Pharmaceuticals, Inc.'s Counterclaims,Cephalon, Inc., and Anesta AGv.Mylan Pharmaceuticals, Inc., Mylan, Inc., Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Civil Action No. 1:08-cv-00889-SLR, filed with the United States District Court for the District of Delaware on Jan. 30, 2009.
Eurand, Inc., Cephalon, Inc., and Anesta AG's Notice of Voluntary Dismissal,Eurand, Inc., Cephalon, Inc., and Anesta AGv.Mylan Pharmaceuticals, Inc., and Mylan, Inc., Civil Action No. 1:08-cv-00210-IMK, filed with the United States District Court for the Northern District of West Virginia on Feb. 23, 2009.
Clevenger James M.
Venkatesh Gopi
Barham Bethany
Cooley Godward Kronish LLP
Eurand Inc.
Woodward M P
LandOfFree
Modified release dosage forms of skeletal muscle relaxants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified release dosage forms of skeletal muscle relaxants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified release dosage forms of skeletal muscle relaxants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4147091